

Samuel J Klempner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4340731/publications.pdf>

Version: 2024-02-01

162
papers

5,684
citations

100601

38
h-index

107981

68
g-index

168
all docs

168
docs citations

168
times ranked

8360
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses. <i>Advances in Radiation Oncology</i> , 2022, 7, 100807.	0.6	4
2	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 71-83.	3.2	37
3	Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. <i>Cancer Prevention Research</i> , 2022, 15, 265-272.	0.7	7
4	ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100330.	1.5	3
5	Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. <i>Lung Cancer</i> , 2022, 164, 52-55.	0.9	8
6	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
7	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 511-524.	0.8	1
8	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 167-192.	2.3	562
9	Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors. <i>Cancer Discovery</i> , 2022, 12, 602-603.	7.7	0
10	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
11	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1282-1293.	7.7	28
12	Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	7.7	52
13	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23.	1.0	1
14	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	1.5	8
15	Abstract 3088: The efficient utilization of paracrine support from established cell lines for breast/ovarian cancer model generation. <i>Cancer Research</i> , 2022, 82, 3088-3088.	0.4	0
16	Abstract 639: Rapidly evaluating cancer dependencies by label-free imaging of zero-passage primary cells. <i>Cancer Research</i> , 2022, 82, 639-639.	0.4	0
17	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6570-6570.	0.8	0
18	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	2.0	7

#	ARTICLE	IF	CITATIONS
19	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€”A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	0.8	2
20	Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)â€”ILUSTRO Cohort 3.. Journal of Clinical Oncology, 2021, 39, TPS260-TPS260.	0.8	5
21	LY3022855, an antiâ€”colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Investigational New Drugs, 2021, 39, 1057-1071.	1.2	26
22	HIPEC for colorectal peritoneal metastases. Lancet Oncology, The, 2021, 22, 162-164.	5.1	16
23	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist, 2021, 26, 651-659.	1.9	5
24	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	3.2	178
25	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€”High Gastric Cancer. Cancer Discovery, 2021, 11, 2168-2185.	7.7	105
26	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RASâ€”MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922.	7.7	243
27	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. Journal of Clinical Oncology, 2021, 39, 4045-4045.	0.8	2
28	Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).. Journal of Clinical Oncology, 2021, 39, e16078-e16078.	0.8	0
29	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 6560-6560.	0.8	0
30	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncology Practice, 2021, 17, e1846-e1855.	1.4	9
31	Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.. Journal of Clinical Oncology, 2021, 39, e16063-e16063.	0.8	6
32	Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from <sc>REGARD</sc>, <sc>RAINBOW</sc>, and <sc>RAINFALL</sc> Phase <sc>III</sc> Studies. Oncologist, 2021, 26, e1538-e1547.	1.9	19
33	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	3.2	8
34	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology, 2021, 5, 1325-1338.	1.5	14
35	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Current Treatment Options in Oncology, 2021, 22, 100.	1.3	11
36	Metabolomics as a Tool for Biomarker Discovery in Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1601-1603.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
38	Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2240-2249.	1.9	20
39	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	1.7	13
40	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154.	0.8	0
41	Increased T-cell receptor repertoire diversity to predict better overall survival in gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 474-474.	0.8	0
42	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	0.7	3
43	393â€¦A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. , 2021, 9, A426-A426.		2
44	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138432.	2.8	8
45	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. <i>Oncologist</i> , 2020, 25, e147-e159.	1.9	220
46	The Panâ€¦Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	1.9	13
47	Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma. <i>Gut</i> , 2020, 69, 630-640.	6.1	68
48	Revisiting<i>MET</i>: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic,<i>MET</i>-Amplified Esophagogastric Cancers. <i>Oncologist</i> , 2020, 25, e1691-e1700.	1.9	1
49	A Spaceâ€¦Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 6401-6403.	3.2	3
50	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
51	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 639-644.	1.9	41
52	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619.	1.5	11
53	Endoscopic History and Provider Characteristics Influence Gastric Cancer Survival in Asian Americans. <i>Cancer Prevention Research</i> , 2020, 13, 773-782.	0.7	1
54	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. <i>Frontiers in Oncology</i> , 2020, 10, 225.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Genomic Alterations of <i>NTRK</i> , <i>POLE</i> , <i>ERBB2</i> , and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1671-e1680.	1.9	17
56	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.2	42
57	High-level <i>FGFR2</i> amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020, 216, 152878.	1.0	21
58	Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. <i>Pancreas</i> , 2020, 49, e19-e20.	0.5	6
59	Can the Help Match the Hype? <i>KRASG12C</i> -Specific Inhibitors and Beyond. <i>Cancer Discovery</i> , 2020, 10, 20-22.	7.7	16
60	Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. <i>JAMA Network Open</i> , 2020, 3, e203652.	2.8	19
61	Lineage-Specific Epigenomic and Genomic Activation of Oncogene <i>HNF4A</i> Promotes Gastrointestinal Adenocarcinomas. <i>Cancer Research</i> , 2020, 80, 2722-2736.	0.4	37
62	Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4543-4543.	0.8	3
63	Analysis of weight loss as a prognostic factor in patients (pts) with advanced gastric cancer from REGARD, RAINBOW and RAINFALL phase III studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 348-348.	0.8	1
64	<i>DKN-01</i> in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral <i>DKK1</i> expression as a predictor of response and survival.. <i>Journal of Clinical Oncology</i> , 2020, 38, 357-357.	0.8	13
65	A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS780-TPS780.	0.8	1
66	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 377-389.	0.8	3
67	Correlation of radiomics of metastatic lesions in gastroesophageal adenocarcinoma (GEA) with tumoral <i>DKK1</i> mRNA expression and other immune biomarkers in patients (pts) treated with <i>DKN-01</i> .. <i>Journal of Clinical Oncology</i> , 2020, 38, 429-429.	0.8	0
68	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 833-833.	0.8	0
69	Impact of palliative care in patients with metastatic esophageal cancer declining chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 315-315.	0.8	0
70	The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16564-e16564.	0.8	0
71	Alterations of DNA damage repair genes in Chinese colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16121-e16121.	0.8	1
72	Targeted next generation sequencing to expand <i>HER2</i> status detection: Implication for newer <i>HER2</i> -directed agents.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1047-1047.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Assessment of FcγRIIIA single nucleotide polymorphisms (SNPs) on the efficacy of IgG1 monoclonal antibodies (mAbs) in PANGEA study patients (pts) with advanced gastroesophageal adenocarcinoma (aGEA).. Journal of Clinical Oncology, 2020, 38, 4526-4526.	0.8	0
74	Baseline features predicting receipt of chemotherapy in metastatic esophageal cancer: A National Cancer Database analysis of 12,370 patients.. Journal of Clinical Oncology, 2020, 38, 316-316.	0.8	0
75	Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 393-393.	0.8	1
76	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186.	0.8	0
77	262â€...Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01. , 2020, , .		0
78	317â€...A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. , 2020, , .		2
79	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025.	0.8	118
80	Ramucirumab plus pembrolizumab: can we make the maths work?. Lancet Oncology, The, 2019, 20, 1041-1043.	5.1	1
81	<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	1.9	16
82	511 â€“ Endoscopic History Potentially Explains Survival Differences Among Asian Americans with Gastric Cancer. Gastroenterology, 2019, 156, S-100.	0.6	0
83	Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2019, 14, 1875-1877.	0.5	1
84	Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 1222.	1.3	14
85	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends in Cancer, 2019, 5, 677-692.	3.8	43
86	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clinical Colorectal Cancer, 2019, 18, 307-309.	1.0	6
87	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Translational Gastroenterology and Hepatology, 2019, 4, 63-63.	1.5	12
88	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. Journal of Hematology and Oncology, 2019, 12, 50.	6.9	44
89	Keeping Checkpoint Inhibitors in Check. JAMA Network Open, 2019, 2, e192546.	2.8	9
90	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Annals of Oncology, 2019, 30, 1096-1103.	0.6	456

#	ARTICLE	IF	CITATIONS
91	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	0.6	224
92	Dr. Samuel J. Klempner: collaborations with Asian countries speed up gastric cancer research. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 82-83.	0.7	0
93	Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. <i>Cancer Discovery</i> , 2019, 9, 166-168.	7.7	4
94	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	1.9	73
95	Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor-Resistant Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	3
96	Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.	1.9	23
97	A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. <i>EBioMedicine</i> , 2019, 40, 375-381.	2.7	85
98	TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. <i>Acta Medica Academica</i> , 2019, 48, 116.	0.3	12
99	Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter. <i>Annals of Oncology</i> , 2018, 29, 801-802.	0.6	10
100	Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018, 23, 518-523.	1.9	40
101	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. <i>Clinical Cancer Research</i> , 2018, 24, 1881-1890.	3.2	59
102	Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 242-249.	0.9	74
103	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	1.5	24
104	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
105	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.	0.6	6
106	Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 560-572.	0.6	9
107	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR- \pm N848K mutation. <i>Lung Cancer</i> , 2018, 124, 86-89.	0.9	0
108	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1312-1323.	0.5	103

#	ARTICLE	IF	CITATIONS
109	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. <i>World Journal of Gastroenterology</i> , 2018, 24, 2686-2697.	1.4	23
110	Abstract 4335: High incidence of POLE and POLD1 mutations in Chinese colorectal cancer patients identified by comprehensive genomic profiling. , 2018, , .		0
111	Abstract 5543: Low ATM expression is associated with improved progression-free and overall survival in advanced gastric cancer patients treated with platinum-based chemotherapy. , 2018, , .		0
112	Samuel J. Klemptner: approaching gastric cancer questions from different angles increases the chance of success. <i>Translational Cancer Research</i> , 2018, 7, S806-S809.	0.4	0
113	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. <i>Oncologist</i> , 2017, 22, 152-157.	1.9	9
114	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 446-457.	0.5	75
115	Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1857-1858.	0.5	0
116	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, 137-140.	0.5	102
117	Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 152-156.	0.5	78
118	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	3
119	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	1
120	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
121	Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 241-247.	1.3	12
122	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
123	ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements. <i>Annals of Translational Medicine</i> , 2017, 5, 173-173.	0.7	3
124	The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis. <i>Journal of Carcinogenesis</i> , 2017, 16, 3.	2.5	20
125	Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 91-97.	1.3	7
126	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 65.	1.2	8

#	ARTICLE	IF	CITATIONS
127	Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. <i>Lung Cancer</i> , 2016, 96, 15-18.	0.9	19
128	<i>BRAF</i> V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to <i>BRAF</i> – <i>MEK</i> Combination Therapy. <i>Cancer Discovery</i> , 2016, 6, 594-600.	7.7	75
129	Radiation dermatitis caused by a bolus effect from an abdominal compression device. <i>Medical Dosimetry</i> , 2016, 41, 221-224.	0.4	2
130	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
131	Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers. <i>Radiotherapy and Oncology</i> , 2016, 118, 430-436.	0.3	41
132	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
133	Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach. <i>Clinical Oncology</i> , 2016, 28, e35-e44.	0.6	15
134	A novel acquired <i>ALK</i> F1245C mutation confers resistance to crizotinib in <i>ALK</i> -positive NSCLC but is sensitive to ceritinib. <i>Lung Cancer</i> , 2016, 92, 19-21.	0.9	32
135	Identification of <i>BRAF</i> Kinase Domain Duplications Across Multiple Tumor Types and Response to <i>RAF</i> Inhibitor Therapy. <i>JAMA Oncology</i> , 2016, 2, 272.	3.4	18
136	<i>ALK</i> F1174V mutation confers sensitivity while <i>ALK</i> I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. <i>Lung Cancer</i> , 2016, 91, 70-72.	0.9	46
137	Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?. <i>International Neurourology Journal</i> , 2016, 20, S131-140.	0.5	20
138	Moving molecular subtypes to the clinic in gastric cancer. <i>Translational Cancer Research</i> , 2016, 5, S25-S30.	0.4	1
139	Focal Hepatic Fluorodeoxyglucose Uptake Mimics Liver Metastasis Following External Beam Radiation for Gastroesophageal Cancers: A Case and Review of the Literature. <i>Journal of Clinical Imaging Science</i> , 2016, 6, 30.	0.4	0
140	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015, 20, 1132-1139.	1.9	84
141	Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in <i>ALK</i> -positive NSCLC: Implications for disease assessment and management. <i>Lung Cancer</i> , 2015, 88, 355-359.	0.9	31
142	Emergence of <i>RET</i> rearrangement co-existing with activated <i>EGFR</i> mutation in <i>EGFR</i> -mutated NSCLC patients who had progressed on first- or second-generation <i>EGFR</i> TKI. <i>Lung Cancer</i> , 2015, 89, 357-359.	0.9	82
143	<i>PTEN</i> loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , 2015, 9, 1694-1703.	2.1	47
144	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	1.9	64

#	ARTICLE	IF	CITATIONS
145	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-“Small-Cell Lung Cancer: A Mini-Review. <i>Clinical Lung Cancer</i> , 2015, 16, 334-339.e1.	1.1	28
146	Identification and characterization of <i>RET</i> fusions in advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 28929-28937.	0.8	94
147	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 561-9.	0.6	61
148	Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. <i>Chinese Clinical Oncology</i> , 2015, 4, 20.	0.4	14
149	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. <i>Translational Lung Cancer Research</i> , 2015, 4, 649-52.	1.3	2
150	Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment. <i>Oncologist</i> , 2014, 19, 1008-1010.	1.9	32
151	Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 549-553.	0.5	155
152	Identification of a Novel HIP1-ALK Fusion Variant in Non-“Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1821-1825.	0.5	91
153	Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 232-237.	3.3	59
154	What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway. <i>Cancer Discovery</i> , 2013, 3, 1345-1354.	7.7	131
155	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2171-2182.	0.9	16
156	Safety of Cupping During Bevacizumab Therapy. <i>Journal of Alternative and Complementary Medicine</i> , 2013, 19, 729-731.	2.1	5
157	The PI3K Pathway in Colorectal Cancers. , 2013, , 157-199.		1
158	Abstract 4265: Derivation and characterization of endometrial cancer cells resistant to phosphatidylinositol-3-kinase (PI3K) pathway inhibitors.. , 2013, , .		0
159	Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients. <i>Journal of Clinical Oncology</i> , 2012, 30, e264-e268.	0.8	42
160	Complementary and Alternative Medicines in Prostate Cancer: From Bench to Bedside?. <i>Oncologist</i> , 2012, 17, 830-837.	1.9	35
161	ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1439-1440.	0.5	18
162	Anti-Yo Antibody Associated With Occult Fallopian Tube Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 536-538.	0.9	8